Close menu




August 21st, 2023 | 07:15 CEST

Meyer Burger, Saturn Oil + Gas, CureVac - Incisive events

  • Mining
  • Oil
  • Biotechnology
  • Technology
Photo credits: pixabay.com

The past week in the stock market, due to the earnings season for the year's first half, brought surprises on both sides. Some companies were able to shine despite uncertainties on the economic and geopolitical side and face a golden future due to a significant undervaluation. Speaking of the future: Due to weaker market conditions, one company after another is leaving the old contingent to take advantage of better conditions overseas.

time to read: 3 minutes | Author: Stefan Feulner
ISIN: MEYER BUR.TECH.NAM.SF-_05 | CH0108503795 , Saturn Oil + Gas Inc. | CA80412L8832 , CUREVAC N.V. O.N. | NL0015436031

Table of contents:


    Meyer Burger - Goodbye Germany

    Since 2006, VOX has been following Germans who want to try their luck abroad in the docu-soap "Goodbye Deutschland! Die Auswanderer". The show focuses on people who long for sun and sea or see no career prospects in "good old Germany." Due to the lack of future prospects, however, even large companies are now joining the trend, especially since the exploding energy costs. Meyer Burger, the only solar cell manufacturer in Europe, has announced its decision. The Swiss company is shifting its strategic focus from Europe to the US, at least for the time being.

    This results from the unfavorable market conditions in Europe, characterized by unprotected competition with producers selling far below their production costs. Meyer Burger emphasized that more favorable production conditions exist in the US, while in Germany, they are under pressure from Chinese suppliers flooding the market with low-cost modules. In July, Meyer Burger announced that it would pause its planned expansion in Saxony-Anhalt and instead invest in Colorado, US.

    Between the two, Swiss solar company Meyer Burger further consolidated its position in the first half of 2023, releasing sales figures showing a 70.8% YOY increase. However, price pressure from Chinese suppliers flooding the market with cheap modules made things difficult. Nevertheless, the Company managed to maintain stable sales prices in the first quarter - special effects due to impairments and credit notes depressed earnings by CHF 13.0 million. An increase in personnel and operating costs, particularly due to the start-up of new production lines, resulted in an operating loss of CHF 43.3 million. The net loss amounted to CHF 64.8 million, whereas liquidity stood at CHF 370 million and the equity ratio at 45.9%.

    With the publication of the figures, the Meyer Burger share continued its months-long slide to CHF 0.406. Since mid-July, when a sales warning was announced, the stock has lost around 38%.

    Saturn Oil + Gas - Records upon records

    In complete contrast to the Swiss solar cell producer, the Canadian producer of light oil, natural gas and natural gas liquids, Saturn Oil & Gas, was able to report record results due to successfully completed acquisitions over the past two years. In this regard, the end of the second quarter marks a significant milestone following the complete integration of Ridgeback Resources.

    YOY quarterly production increased to 25,988 barrels of oil equivalent per day (boe/d), compared to 7,324 boe/d in the second quarter of 2022, while resulting quarterly revenue also reached record highs of CAD 176.0 million, compared to CAD 82.2 million in the year-ago quarter.

    The Company, led by CEO John Jeffrey, achieved another record high with an adjusted cash flow of CAD 67.0 million, or CAD 0.48 per share. The comparable figure for the previous year of CAD 14.5 million was thus pulverized. At the same time, net operating income, net of derivatives, is a high CAD 41.87 per barrel of oil equivalent, while the benchmark WTI oil price for the period was USD 73.75.

    Saturn's financial strength is also reflected in its consistent debt reduction. Repayments of a substantial CAD 51.5 million were made during the quarter, underscoring the Company's determination to maintain a strong balance sheet and proactively reduce financial obligations.

    Canaccord Genuity analysts continue to see Saturn Oil as a speculative buy candidate following the quarterly results, which met their set forecasts and reiterated their price target of CAD 6.50. The current share price represents an upside potential of around 146%.

    CureVac - Loss widened

    Compared to its peer group, the vaccine manufacturer CureVac has clearly outperformed since the beginning of the year with a price increase of around 53% but bounced off its 200-day line at USD 10.14 due to weak half-year figures. The share is currently trading at USD 8.91. The chart picture would brighten if the downward trend at USD 9.96 formed at the end of June were overcome. In the south, however, the upward trend established since the beginning of the year at USD 7.61 is of importance.

    The financial results for the first half of 2023 showed a mixed picture. While the Company's cash position increased from EUR 495.8 million at the end of 2022 to EUR 537.9 million in June 2023, mainly thanks to a capital increase in February, CureVac saw a marked decline in sales. Compared to the same period last year, revenues fell 62.2% in the second quarter and as much as 67.0% for the first half of 2022, mainly due to declining revenues from collaborations with GSK.

    The operating loss, on the other hand, increased significantly from minus EUR 75.6 million to minus EUR 132.2 million compared to the same period last year, also due to increased research and development expenses in the areas of infectious diseases and oncology. In addition, patent disputes, in particular a lawsuit against Pfizer/BioNTech in Germany, had a negative impact.


    Saturn Oil & Gas reported record second-quarter figures. In contrast, solar cell manufacturer Meyer Burger and biotech company CureVac both struggled with rising losses.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.


    Der Autor

    Stefan Feulner

    The native Franconian has more than 20 years of stock exchange experience and a broadly diversified network.
    He is passionate about analyzing a wide variety of business models and investigating new trends.

    About the author



    Related comments:

    Commented by Nico Popp on April 25th, 2025 | 07:20 CEST

    US biotechs under pressure – Where opportunities now lie: BioNTech, Pfizer, and Vidac Pharma

    • Biotechnology
    • Biotech
    • Pharma

    The biotech world is in turmoil. The dispute between US President Donald Trump and the elite Harvard University is just the tip of the iceberg – thousands of researchers in the US are upset about the interference in their academic freedom. Research funding is being cut because of supposedly incorrect wording in applications. Entire degree programs are being put on hold because they do not fit into the worldview of the new US administration. The National Security Commission on Emerging Biotechnology (NSCEB) is warning of dire consequences for the US economy. Is the United States losing its status as a biotech mecca?

    Read

    Commented by André Will-Laudien on April 25th, 2025 | 07:10 CEST

    Crash or rebound? Tracking the data with Palantir, SAP, MiMedia, and Deutsche Telekom

    • Software
    • Digitization
    • Technology
    • Telecommunications

    Is the big correction already over? Given historically high liquidity, investors are wondering whether last week's slump marked the end of the road. Stocks such as Nvidia, Apple and SAP have now corrected more than 25% from their highs, something that has rarely been seen in the last 24 months. The NASDAQ is tentatively working its way back up, but the DAX 40 index is gaining momentum. It is now only 1,500 points away from its previous high of 23,476 points. A good strategy could, therefore, be to selectively re-enter the market. However, set clear loss limits for each investment. Here are a few promising suggestions.

    Read

    Commented by Fabian Lorenz on April 25th, 2025 | 07:00 CEST

    RENK BEFORE TAKEOVER? Will Evotec and AI gem NetraMark be swallowed up?

    • Biotechnology
    • Biotech
    • Defense

    Is RENK on the verge of a takeover? In any case, the antitrust authorities have approved the entry of a new major shareholder. Could the takeover of the gearbox manufacturer herald a consolidation in the European defense industry, as announced by the head of Hensoldt? So far, there have only been small acquisitions, such as those of Rheinmetall. There is also movement in the pharmaceutical and biotech sectors. The Trump tariffs are shaking up the industry. NetraMark's AI software helps reduce costs and save time in drug research. The AI insider tip's stock still appears cheap and could skyrocket amid takeover speculation. Evotec has also been repeatedly mentioned as a takeover candidate. Yesterday, a large milestone payment was reported. How are the shares performing?

    Read